VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

NYVAC-PRV- gII/ gp50
Vaccine Information
  • Vaccine Name: NYVAC-PRV- gII/ gp50
  • Target Pathogen: Pseudorabies virus
  • Target Disease: Aujeszky's disease
  • Vaccine Ontology ID: VO_0004778
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GII gene engineering:
    • Type: Recombinant vector construction
    • Description: A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996).
    • Detailed Gene Information: Click Here.
  • gp50 gene engineering:
    • Type: Recombinant vector construction
    • Description: A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996).
    • Detailed Gene Information: Click Here.
  • Vector: NYVAC vaccine vector
  • Preparation: (Brockmeier and Mengeling, 1996) A NYVAC vaccinia vector containing genes for PRV gII and gp50 .
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Pig Response

  • Vaccination Protocol: The pigs were vaccinated via intramuscular injection in the thigh with 107 CCID50 of NYVAC/gp50 or NYVAC/gpII,gp50, 4 weeks apart (Brockmeier and Mengeling, 1996).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Vaccinated pigs were challenged with 108 PFU of Indiana-Funkhauser strain of PRV oronasally, 4 weeks after the second vaccination (Brockmeier and Mengeling, 1996).
  • Efficacy: Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge (Brockmeier and Mengeling, 1996).
References
Brockmeier and Mengeling, 1996: Brockmeier SL, Mengeling WL. Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1996; 60(4); 315-317. [PubMed: 8904669].